Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

M.H.G. Langenberg, P.O. Witteveen, J.M. Roodhart, H.M.W. Verheul, M. Mergui-Roelvink, J. van der Sar, E. Brendel, N. Laferriere, J.H.M. Schellens, E.E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2187-2197
JournalClinical Cancer Research
Volume16
Issue number7
DOIs
Publication statusPublished - 2010

Cite this

Langenberg, M.H.G. ; Witteveen, P.O. ; Roodhart, J.M. ; Verheul, H.M.W. ; Mergui-Roelvink, M. ; van der Sar, J. ; Brendel, E. ; Laferriere, N. ; Schellens, J.H.M. ; Voest, E.E. / Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 7. pp. 2187-2197.
@article{edf207e978e245aba067132cbec8e3a0,
title = "Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors",
author = "M.H.G. Langenberg and P.O. Witteveen and J.M. Roodhart and H.M.W. Verheul and M. Mergui-Roelvink and {van der Sar}, J. and E. Brendel and N. Laferriere and J.H.M. Schellens and E.E. Voest",
year = "2010",
doi = "10.1158/1078-0432.CCR-09-2436",
language = "Undefined/Unknown",
volume = "16",
pages = "2187--2197",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. / Langenberg, M.H.G.; Witteveen, P.O.; Roodhart, J.M.; Verheul, H.M.W.; Mergui-Roelvink, M.; van der Sar, J.; Brendel, E.; Laferriere, N.; Schellens, J.H.M.; Voest, E.E.

In: Clinical Cancer Research, Vol. 16, No. 7, 2010, p. 2187-2197.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

AU - Langenberg, M.H.G.

AU - Witteveen, P.O.

AU - Roodhart, J.M.

AU - Verheul, H.M.W.

AU - Mergui-Roelvink, M.

AU - van der Sar, J.

AU - Brendel, E.

AU - Laferriere, N.

AU - Schellens, J.H.M.

AU - Voest, E.E.

PY - 2010

Y1 - 2010

U2 - 10.1158/1078-0432.CCR-09-2436

DO - 10.1158/1078-0432.CCR-09-2436

M3 - Article

VL - 16

SP - 2187

EP - 2197

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -